Corporate B2B / Key Worker — The killer tax fact

Author: Research dossier for DoctoriumGP men's longevity launch Date: 25 April 2026 Scope: UK owner-operator £2–10m turnover companies, executive medicals, B2B longevity, ROI case, tax position, sales motion Status: Hard-data dossier. Citations inline. UK English throughout.

---

Executive summary

The UK has a mature corporate executive-medical market dominated by Bupa, Nuffield, Spire and Bluecrest, but it sells a 20th-century product: a one-day ticked-box health screen at £250–£1,065 per head, with no longitudinal layer, no hormone optimisation, no GLP-1 pathway and no behaviour-change loop. Above that sits a thin layer of premium "longevity" clinics (Echelon at £6k–£14k per assessment; HUM2N, HOOKE, Lanserhof) which are priced for individuals, not corporate fleets, and sell almost entirely B2C. There is no scaled UK player selling longitudinal longevity-medicine memberships to SME owner-operators as a key-worker retention benefit. That is the gap DoctoriumGP can occupy.

The buying case for the owner-operator is unusually clean: - HMRC EIM21765 lets the company pay for one health-screen + one medical per employee per tax year with zero benefit-in-kind, provided it's offered to all employees (or all those flagged by screening). ¹ - Corporation tax relief applies to all genuine staff health spend under the wholly-and-exclusively rule. ² - PMI premiums are deductible to the company but a BIK to the employee. Group PMI inflation hit 18.8% in the most recent Aon read — claims inflation is 12% — so SMEs are looking for alternatives. ³ - Sickness absence is at a 15-year high: 9.4 days per employee in 2024 (vs 5.8 pre-pandemic), costing SMEs £547 per employee per year or a median £27,964 per business per year. ⁴⁵ - Presenteeism alone costs UK firms 49.7 productivity days per employee per year; 90% of all lost productivity is presenteeism, not absence. ⁶ - Replacing one mid-senior employee costs £30,614 average; legal/professional roles £39,887; a director with 28 weeks to optimum productivity carries an attached cost of £25,181 in productivity ramp alone. ⁷ - 53% of UK SMEs would cease trading inside 12 months if a key person died or became critically ill. ⁸

Recommendation: pursue B2B as a parallel revenue line. Run founder-led for first 12 months, no BD hire. Build four tiers (Director Health, Key Person 5-pack, Executive Wellness Programme, On-site Mobile Day). 12-month target: 15 SME clients, £180k–£270k ARR. 36-month target: 50 SME clients, £750k–£1.1m ARR.

---

A. The UK executive medical / corporate health screen market

A.1 Pricing matrix — published rates

Market average for an "executive medical" delivered by a recognised brand: £750–£1,200 per head, single-shot, no follow-through.

A.2 Premium longevity tier (where DGP is positioned)

Verdict on competitor landscape: None of the premium longevity players sell a packaged, productised, longitudinal corporate offer for SMEs at the £3k–£6k per-head/year band. Echelon comes closest but is one-shot imaging, not ongoing care. The £750–£1,500 brand-name medicals (Bupa/Nuffield) are tick-box; the £6k+ players are bespoke and individual.

The white space: longitudinal, productised, key-worker-focused longevity membership at £2.5k–£5k/employee/year, sold as a package to a £2–10m turnover SME with 1–10 directors / key staff.

---

B. The cost of ill-health to UK employers — the ROI sell

B.1 Sickness absence

• 9.4 days lost per employee per year (CIPD Health & Wellbeing at Work 2024, surveyed in 2025 report) — up from 7.8 in 2023, 5.8 pre-pandemic. 15-year high. ⁴
• SMEs lose 9.1 days per employee/year. ⁵
• Cost: £547 per employee/year for an SME under 250 staff. ⁵
• Median total cost per SME business: £27,964/year, equivalent to 1.7% of total turnover. ⁵
• Top long-term causes: mental ill-health (41%), MSK (31%), other long-term conditions (30%). ⁴

B.2 Presenteeism — the bigger number

• 49.7 productivity days lost per employee per year, of which 90% is presenteeism (Vitality / RAND Britain's Healthiest Workplace 2024). ⁶
• Total UK economy hit: £138bn/year from poor workplace health. ⁶
• Depression-risk employees lose 109 days/year; burnout-risk lose 93 days. Healthy peers lose 42–43. ⁶

For a £5m turnover SME with 30 staff that's ~30 × 49.7 = ~1,491 lost productivity days/year. At £200/day fully-loaded labour cost that's ~£298k of recoverable productivity drag per year — roughly 6% of revenue.

B.3 Mental health

• Poor mental health costs UK employers £51bn/year (Deloitte 2024), down from £55bn in 2021 but up from £45bn in 2019. ¹⁵
• Presenteeism alone = £24bn of that. ¹⁵
• ROI on mental-health investment: £4.70 per £1 spent (Deloitte 2024 meta-analysis of 26 studies). ¹⁵
• Universal interventions: £6.30 per £1. Proactive: £4.20. Reactive: £4.10. ¹⁵
• EAP-specific ROI: £10.85 per £1 (EAP Association). ¹⁵

B.4 Replacement cost when you lose a key person

• Average replacement cost £30,614 per role (Oxford Economics). ⁷
• 28 weeks to optimum productivity = additional £25,181 cost-of-ramp. ⁷
• Legal / professional roles: £39,887. ⁷
• 53% of UK SMEs would cease trading within 12 months if a key person died or was critically ill (Legal & General). ⁸
• Sole-director risk: if the sole director/shareholder dies, probate must complete before the company can pay suppliers, sign contracts or pay staff. Weeks of paralysis. Pre-2009 incorporated companies under Table A have no Model Articles fall-back — practical impasse. ¹⁶

B.5 The owner-operator £5m business case — quantified

For a £5m turnover, 30-staff SME with 3 key directors:

Annualised expected cost of ill-health for the £5m SME: ~£250k–£400k. Spending £30k–£60k/year on a longevity programme covering MD + key staff is a 5–10× ROI even on conservative assumptions.

---

C. The UK tax position — the no-brainer sell

This is the most under-exploited part of the pitch. Most directors do not know any of this.

C.1 Annual employer-paid health screen + medical check-up — BIK exempt

HMRC EIM21765: an employer can provide one health-screening assessment + one medical check-up per employee per tax year with no taxable benefit in kind — provided it's offered generally to all employees (or all those flagged by screening as needing follow-up). ¹

• Spouse/partner/family screen = taxable unless they're also employees. ¹
• Treatment/diagnosis costs fall outside this exemption (those are PMI/treatment costs, taxable as BIK if employer-paid). ¹
• Vouchers/credit-tokens for screening also covered. ¹

This is the single most important fact in the sales pitch. The first £1k of DGP's longevity baseline can be delivered as a tax-free benefit to every staff member.

C.2 Corporation tax deductibility

Health screening, medicals, PMI premiums and most workplace wellbeing spend pass the wholly-and-exclusively-for-trade test under HMRC rules. The company deducts the cost from profit before CT (currently 19–25%). ²

• For a £5m turnover SME paying 25% CT, every £10k spent on staff health = £2,500 of CT relief.
• Net cost of a £30k corporate longevity package = £22,500 post-CT relief.

C.3 PMI as BIK

When a company pays group PMI: - Company: premium is CT-deductible. ⁹ - Employee/director: taxable BIK on full premium value, paid via P11D / from April 2026 via payroll. ⁹ - Class 1A NIC payable by employer on the BIK value. ⁹

For a 40% taxpayer with £1,500 PMI premium: BIK tax = £600. Employee feels the policy as worth £900 net. A health screen under EIM21765 of equivalent value carries £0 tax.

C.4 Trivial benefits — directors of close companies

HMRC EIM21870: trivial benefits ≤£50, non-cash, non-contractual, not performance-linked = exempt. Director cap of £300/year across multiple gifts. ¹⁰

Limited use for longevity (the value-per-touch is too high) — but useful for top-up perks (supplement boxes, branded recovery kit) layered on top of the main programme.

C.5 Director medicals — "wholly, exclusively, necessarily"

Where medical treatment is necessary in the performance of duties (e.g. work-related injury), the company can pay tax-free. Beyond that, the standard EIM21765 exemption for one screen + one medical per year applies to directors as it does to other employees. ²

C.6 VAT

Medical services provided by registered medical professionals are exempt from VAT. Diagnostics/blood tests delivered as part of a medical service: typically exempt. Supplements, devices, retail products: 20% VAT. Companies cannot recover input VAT on exempt supplies — a small but real margin consideration when packaging. [Standard HMRC VAT Notice 701/57 — medical services]

C.7 Salary sacrifice

PMI / health screens generally not advantageous via salary sacrifice post-2017 (OpRA rules removed the NIC saving on most non-pension/non-EV BIKs). Some plans still work for cycle-to-work, ULEV cars, pension and childcare — but for medical it's a wash. Direct employer payment under EIM21765 is the cleaner route. [HMRC OpRA guidance]

C.8 The headline tax pitch (one slide for the SME owner)

For a £5m turnover company paying 25% Corporation Tax, a £30,000 director-and-key-staff longevity package costs the company £22,500 net. The annual screen component is delivered with zero P11D benefit in kind on every employee. Compare to private spend: a £30,000 personal payment from post-tax income means a 40% taxpaying director needs to earn £50,000 gross to fund it. The corporate route is 2.2× more efficient.

---

D. The UK B2B longevity gap — what exists, what doesn't

Who currently sells longevity B2B in the UK? - Echelon Health — bespoke corporate bookings, no published tier. Imaging-led, not longitudinal. - HUM2N, HOOKE, Lanserhof — capacity for HNW individuals from corporates, but no off-the-shelf SME package. - Bluecrest — sells "executive" but it's a one-day screen, not longevity. - Spire / HCA / Cleveland Clinic London — corporate health packages but framed as occupational health, not optimisation. - PMI brokers (Engage Health Group, Punter Southall, Howden) — sell PMI not longevity, but advise SMEs on benefits stack.

Are there any UK clinics doing 100% B2B / corporate longevity? No identified player. The market is either: - B2C luxury (Lanserhof, HOOKE, HUM2N at £6k–£25k/year individual), or - B2B mass screening (Bluecrest, Nuffield at £130–£400/head one-shot).

Hone Health (US) reference model: $129–$149/month subscription, $65 lab-test entry, $225 average customer monthly out-of-pocket. B2B2C distribution via tech and finance corporate wellness stipends. Has raised $33m total. ¹¹

Function Health (US) reference model: $365/year for 160+ labs + clinician review. Corporate workplace pricing — buy up to 499 memberships at special rate. Tailored executive onboarding with MRI scans, Galleri, brain health add-ons. ¹²

The DGP positioning: UK Function-Health-equivalent, but doctor-led (Gemma MRCS MRCGP), with GLP-1 / HRT / TRT prescribing baked in (legally, in-clinic), and packaged as an SME owner-operator + key-staff product not a self-service consumer subscription. No direct UK competitor.

---

E. Recommended pricing tiers for DGP corporate offer

E.1 Tier structure

E.2 What's included (recommended)

Tier 1 — Director Health (£2,983/director/year) - 1 × Longevity Baseline at month 0 (full bloods, body composition, VO2-max if equipped, HRV, sleep tracker setup, GP consult) - Quarterly medical review with Dr Gemma Lewis (4 × 30-min) - Continuous biomarker dashboard (DGP health dashboard) - GLP-1 / HRT / TRT pathway access (medication priced separately at standard private rate; clinical oversight included) - Annual repeat baseline at month 12 - Direct WhatsApp/Signal line to clinical team for triage - Annual report for the company (anonymised, aggregated trends only — privacy preserved)

Tier 2 — Key Person 5-pack (£2,990/head/year) - As above, branded as employer benefit - HR-friendly onboarding pack - Anonymised aggregate dashboard for the owner-MD: "your team is statistically X risk band" - Trigger-based escalation: any red-flag finding generates company-paid follow-up

Tier 3 — Executive Wellness Programme (£2,495/head/year, min 10) - One on-site mobile day per year: bloods, BMI/body comp, BP, HRV - Individual baselines + 12-month dashboards - Quarterly wellness webinar by Dr Gemma (group) - 1 × group lunch-and-learn at the company HQ - Two clinical 1:1s/year per employee (vs four for Tier 1/2) - GLP-1 / HRT / TRT pathway available at staff option

Tier 4 — On-site Mobile Clinic Day (£8,500 + £225/head) - Day visit by Dr Gemma + nurse + phlebotomist - Onsite bloods (45-marker panel), BP, body composition, brief 15-min GP consult per employee - Same-day initial findings, 7-day full report - Optional: company-funded GLP-1 / HRT / TRT pathway opt-in - Wedge product to upsell to Tier 3 at next renewal

E.3 Revenue and capacity model

Revenue per company per year (typical mix): - Tier 1: £8,950 - Tier 2: £14,950 - Tier 3 (15-head average): £33,400 - Tier 4 day: £11,875 (15 heads) — typically converts 30–40% to Tier 3 within 12 months

Gemma's clinical time per company per year:

Scaling profile (Gemma capacity = ~1,200 clinical hours/year @ 4 days/week clinical):

Inflection: at ~25 SMEs Gemma needs to add a junior clinician (associate GP @ £80–100k FTE) to retain her own bandwidth for clinical leadership. The maths supports it well before that point.

---

F. Owner-operator buying psychology

F.1 Adoption rates in UK SMEs

• 53% of UK SMEs provide PMI (YouGov 2024 survey of 901 SMEs). ¹⁷
• 43% of those plan to expand PMI access in the next 12 months. ¹⁷
• 70% of SMEs provide some form of proactive health promotion, but skewed to larger SMEs. ¹⁸
• Director-only health benefits are extremely common in £2–10m businesses — specific %s not published, but anecdotally 70–80% of owner-operators in this band have at least personal PMI through the company.

F.2 Decision-maker

In a £2–10m company, the buying decision for a new wellness benefit is almost always made by the MD/owner, not HR (most £2–10m SMEs don't have a dedicated HR function — it's the MD, the FD, or an outsourced HR consultant).

The MD is also the prospective primary patient. This is the single most important sales-motion fact. Selling DGP B2B is not classic enterprise B2B — it's selling a B2C personal-health product to the MD, with a coupon for their team attached.

F.3 Trigger events for adding executive health benefits

Sourced from REBA, CIPD and benefits-broker reports: ¹³ 1. Post-PE deal / external investment — new investors mandate key-person protection. 2. Post-near-miss — MD or co-founder has a health scare. 3. After hiring an expensive senior — "we've just paid £150k for this CFO, we need to keep them healthy." 4. PMI renewal shock — 18.8% premium hike forces a benefits review. ³ 5. Competitive pressure on retention — losing a key hire to a competitor with better benefits. 6. Generational handover — second-gen owner more health-conscious. 7. GLP-1 cultural moment — owner has tried GLP-1 personally, wants formalised pathway. 8. Long-COVID / sickness rise — visible drag in the team.

F.4 Sales cycle length

• Tier 1 (Director Health): 2–4 weeks. The MD is also the patient — short personal-buy decision.
• Tier 2 (Key Person 5-pack): 4–8 weeks. Needs FD agreement on budget, brief consult with key staff.
• Tier 3 (Executive Wellness): 8–16 weeks. May involve HR/operations, board-level sign-off.
• Tier 4 (Mobile Day): 1–3 weeks. Cheap, easy, no commitment.

---

G. Sales motion — how to actually sell this

G.1 First conversation

Call the MD. In an SME under £10m turnover, the MD makes the call, sets the budget, and is the patient. Skip HR.

Opener: "You've got a £5m business that depends on three people. If you stopped working for six weeks, what's the revenue hit?" — gets the engagement immediately.

Wedge: "Let me run my own founder's longevity baseline on you. If it's worth it, you decide whether your senior team should have access. £0 commitment for the demo."

G.2 Sales asset suite

Build (all DGP-branded, Cloudflare Pages-deployed): 1. One-pager — "Director Longevity Programme" with HMRC EIM21765 callout box. 2. ROI calculator (web) — input turnover, key-person count, average salary; output annualised expected ill-health cost vs DGP package cost. 3. Two case studies — one Tier 1 (single MD), one Tier 2 (MD + key staff). De-identified with permission. 4. Tax briefing PDF — 2-page summary of EIM21765 + CT relief + BIK position. Send to FD/accountant. 5. Sample dashboard view — anonymised, what the company gets. 6. Capacity-aware booking page — Calendly tied to Dr Gemma's diary.

G.3 Free pilot / wedge offer

Yes — offer the MD a free Longevity Baseline as the wedge to sell the corporate package.

Logic: - £400–£600 cost-of-goods to deliver. - Converts at ~30–40% to Tier 1 in 30 days, ~15–20% to Tier 2/3 in 90 days. - A converted MD becomes the internal champion for staff rollout.

Cap at 4 free baselines/month (1/week of Gemma's time = ~£800 opportunity cost vs £15k–£30k LTV).

G.4 Channel partners

Primary three: 1. Accountants — they file the P11D, see the director salary package, advise on remuneration. Already covered in DGP's warm-channel research. Highest-conversion channel for Tier 1. Offer 10% rev-share on first-year contract value. 2. PMI brokers — Engage Health Group, Punter Southall Health & Protection, Howden, Mercer Marsh Benefits, Equipsme distribution partners. They already have the SME relationship and are watching premiums explode (18.8% inflation). ³ Position as the upsell to their existing PMI book — "we'll add a £2,500/director longevity layer that the company can claim against CT and that addresses the 90% of productivity drag PMI doesn't fix." Offer 15% rev-share. 3. Wealth managers / IFAs — they advise the owner-MD on succession + key-person insurance. Health is upstream of those concerns. Offer 10% rev-share.

Secondary: - HR consultancies serving £2–10m SMEs (e.g. The HR Dept, Citation, Peninsula). - Local FSB / Chamber of Commerce branches as partner channel for awareness events.

G.5 PMI broker partnership angle (highest priority)

UK PMI brokers are under acute pressure: claims inflation 12%, premium inflation 18.8%, employer demand for "more bang for buck". ³ Their existing pitch is being commoditised by Equipsme (PMI lite from £9/employee/month). ¹⁴

Pitch to brokers: "Your client's PMI just went up 18%. We give you a £2.5k/head longevity layer that addresses the 90% of productivity drag PMI never touches, sells on tax + ROI, and pays you 15% recurring revenue. We don't compete with your PMI book — we deepen it."

Target brokers (cold outreach list to build): - Engage Health Group - Punter Southall Health & Protection - Howden Employee Benefits - Mercer Marsh Benefits Elect (their explicit SME product) - Aon Health Solutions UK SME desk - WPA broker network - Equipsme partner brokers - Drewberry (director-focused) - Hooray Health & Protection

A 2026 plan: convert 3 brokers in 12 months = potential ~30–50 SME leads/year.

---

H. Comparable case studies and proof points

H.1 SME owner buys longevity for self + key staff

No published UK case study exists at the SME £2–10m level. This is white space — DGP can build the first 2–3 within 6 months and own the category narrative.

H.2 Comparable proof points to use

1. Britain's Healthiest Workplace 2024 (Vitality/RAND) — £138bn UK economic loss; 49.7 productivity days/employee/year. ⁶
2. Deloitte 2024 Mental Health & Employers — £4.70 ROI per £1 invested in workplace mental health. ¹⁵
3. Hone Health (US) — $55m revenue run-rate from 2019, sustained corporate wellness uptake at tech/finance firms. Cited as proof the model scales. ¹¹
4. Function Health (US) for Work — sells direct to employers at corporate rate; tailored exec onboarding. ¹²
5. Aon "unprecedented" PMI premium rise of 18.8% — proof point that SMEs are forced to review benefits in 2025/26. ³
6. CIPD 2025 Health & Wellbeing report — sickness absence at 15-year high. ⁴

H.3 PMI broker upsell precedent

• Mercer Marsh Benefits Elect is explicitly an SME-tier product designed to be added on top of base PMI. ¹⁹ Direct precedent for layered-benefits sales motion.
• Howden's rationale for "more bang for buck" group PMI is the brokers themselves looking for value-add layers. ³

---

I. Risks and objections — handling

---

J. Recommendation

J.1 Pursue B2B as a parallel revenue line: YES

Rationale: 1. Genuine market gap: no UK player owns SME-tier longevity-as-employer-benefit at £2.5k–£3k/head/year. 2. Tax tailwind: EIM21765 + CT relief makes the company route ~2× more efficient than personal pay. 3. Inflation tailwind: PMI at 18.8% premium inflation forces SME benefit reviews; DGP fits the new spend. 4. Channel tailwind: PMI brokers + accountants both motivated to add a longevity layer. 5. Margin profile: 50–60% gross margin at recommended pricing. 6. Founder fit: Gemma's clinical credibility (MRCS MRCGP) is the differentiator — no other UK longevity B2B has a senior surgeon-GP fronting it.

J.2 Tier structure (final recommendation)

• Tier 1 Director Health: £8,950 / 3 directors / year (£2,983/head)
• Tier 2 Key Person 5-pack: £14,950 / 5 / year (£2,990/head)
• Tier 3 Executive Wellness: £24,950 / 10 / year + £1,995/extra head (£2,495/head)
• Tier 4 Mobile Day: £8,500 + £225/head

J.3 Revenue projection

J.4 Sales investment required

Months 0–12: founder-led (Ade for sales motion + Gemma for clinical). No BD hire. - Build asset suite (one-pager, ROI calculator, tax briefing, dashboard demo, two case studies). - Run 3 broker pilots in months 3–6. - Run 5 accountant partner pilots in months 6–9. - Wedge offer: 4 free MD baselines/month, target 30–40% conversion to Tier 1.

Months 12–24: hire one BD/account manager (£60k OTE) once at 15 SMEs and £180k ARR — paid back inside 6 months at conversion targets.

Months 24–36: add second clinician (£80–100k FTE) when Gemma at ~50% capacity utilisation.

J.5 Risks

1. Gemma capacity — single point of clinical failure until month ~18. Mitigation: locum agreement on standby, second clinician hire trigger at 25 clients.
2. CQC scope — confirm CQC registration covers corporate-contracted multi-site delivery. Likely yes; verify before launch.
3. Data/ICO compliance — corporate dashboard must be aggregate-only; individual data firewalled. Standard occ-health practice; must be airtight in MSAs.
4. PMI broker channel conflict — they may push their existing wellbeing partners. Mitigation: lead with tax + clinical-credibility differentiator; offer 15% rev-share which beats most wellbeing platforms.
5. Client churn at year 2 — if first-year baseline reveals nothing dramatic, MD may not see value. Mitigation: dashboard touchpoints + GLP-1/HRT pathway create stickiness; year-2 metrics show measurable improvement.
6. Brand confusion B2C↔B2B — DGP is also doing menopause B2C. Solve via separate sub-brand for B2B (e.g. "DoctoriumGP Executive" or "DGP at Work") with shared back-office.

J.6 Single-page conclusion

The owner-operator £2–10m SME segment is the highest-value, lowest-competed, most tax-favoured B2B opportunity for DoctoriumGP's longevity offer. The MD is also the patient — buying cycles are short, decision-maker is single. EIM21765, CT relief, 18.8% PMI inflation and 49.7 lost productivity days/employee combine into a defensible ROI pitch nobody in the UK is currently making at this price point. Founder-led for 12 months, then BD hire. 15 clients / £190k ARR / £105k gross profit by month 12 is the realistic base case. 50 clients / £900k ARR / £500k GP by month 36 is the aggressive case and is well within Gemma's clinical capacity once a second clinician joins at month ~24.

Build the asset suite. Pitch the brokers. Wedge with free MD baselines. Don't wait.

---

Footnotes — sources

---

Word count: ~5,100 Last refreshed: 25 April 2026